{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=113",
    "query": {
      "condition": "Dermatologic Disorders",
      "page": 113
    },
    "page_size": 10
  },
  "pagination": {
    "page": 113,
    "page_size": 10,
    "total_count": 13632,
    "total_pages": 1364,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=114&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=112&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T21:46:44.115Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Non Small Cell Lung Cancer",
        "Cervical Cancer",
        "Endocervical Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Bladder Urothelial Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer",
        "Melanoma",
        "Mesothelioma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NGM438",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA ®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2022-05-11",
      "completion_date": "2025-06",
      "has_results": false,
      "last_update_posted_date": "2024-04-01",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05311618"
    },
    {
      "nct_id": "NCT03431610",
      "title": "A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "SB414 2%",
          "type": "DRUG"
        },
        {
          "name": "SB414 6%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novan, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2017-11-13",
      "completion_date": "2018-05-11",
      "has_results": false,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 9,
      "location_summary": "Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Sweetwater",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03431610"
    },
    {
      "nct_id": "NCT02589210",
      "title": "dHACM Mesh In the Treatment of Diabetic Foot Ulcers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcers"
      ],
      "interventions": [
        {
          "name": "EpiFix Mesh",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "MiMedx Group, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2015-05",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2017-08-25",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02589210"
    },
    {
      "nct_id": "NCT01712360",
      "title": "Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tinea Pedis",
        "Tinea Cruris"
      ],
      "interventions": [
        {
          "name": "NAFT500 (pediatric)",
          "type": "DRUG"
        },
        {
          "name": "NAFT600 (pediatric)",
          "type": "DRUG"
        },
        {
          "name": "NAFT500 (adult)",
          "type": "DRUG"
        },
        {
          "name": "NAFT600 (adult)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz North America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 56,
      "start_date": "2012-10",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 2,
      "location_summary": "Austin, Texas • College Station, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712360"
    },
    {
      "nct_id": "NCT05477160",
      "title": "A Study of STAR-0215 in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "STAR-0215 (SC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (SC)",
          "type": "DRUG"
        },
        {
          "name": "STAR-0215 (IV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (IV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astria Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 41,
      "start_date": "2022-07-27",
      "completion_date": "2023-11-17",
      "has_results": false,
      "last_update_posted_date": "2024-01-11",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05477160"
    },
    {
      "nct_id": "NCT05653882",
      "title": "A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Melanoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "etakafusp alfa (AB248)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Asher Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 552,
      "start_date": "2023-01-04",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 20,
      "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05653882"
    },
    {
      "nct_id": "NCT04358224",
      "title": "The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "Dupilumab Prefilled Syringe",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jonathan A. Bernstein, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "19 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2020-09-01",
      "completion_date": "2022-11-18",
      "has_results": false,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04358224"
    },
    {
      "nct_id": "NCT00580333",
      "title": "Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2007-09",
      "completion_date": "2020-06",
      "has_results": true,
      "last_update_posted_date": "2021-05-26",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00580333"
    },
    {
      "nct_id": "NCT07053852",
      "title": "Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Actinic Keratoses",
        "Photodamage"
      ],
      "interventions": [
        {
          "name": "Ameluz",
          "type": "DRUG"
        },
        {
          "name": "Sciton HEROic",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sherrif Ibrahim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-06-27",
      "completion_date": "2025-12-29",
      "has_results": false,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 1,
      "location_summary": "Victor, New York",
      "locations": [
        {
          "city": "Victor",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053852"
    },
    {
      "nct_id": "NCT00070252",
      "title": "Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Solid Neoplasm",
        "Inflammatory Breast Carcinoma",
        "Male Breast Carcinoma",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2003-09",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2015-05-04",
      "last_synced_at": "2026-11-11T21:46:44.115Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00070252"
    }
  ]
}